Sarepta Therapeutics | SRPT - Selling And Administration Expenses

Stock Price
17.79
Daily Change
0.39 2.24%
Monthly
-21.97%
Yearly
-83.52%
Q1 Forecast
17.93

Sarepta Therapeutics reported $77.11M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amgen USD 1.94B 237M Dec/2025
BioCryst Pharmaceuticals USD 80.47M 15.39M Dec/2024
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Capricor Therapeutics USD 5.88M 1.6M Mar/2025
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
Gilead Sciences USD 1.78B 425M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Insmed USD 186.38M 109.94M Sep/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
Moderna USD 308M 40M Dec/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novavax USD 66.95M 34.05M Sep/2024
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 84.05M 1.22M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.75B 455M Dec/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Tectonic Therapeutic USD 4.96M 190K Sep/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025